Brief: Astrazeneca Pharma India Received No Objection From Central Drugs Standard Control Organisation

Astrazeneca Pharma India

14/02/2023 13:22

Feb 14 (Reuters) - Astrazeneca Pharma India Ltd
 ASTR.NS :
    * RECEIVED NO OBJECTION FOR AN ADDITIONAL/EXPANDED
INDICATION FROM
THE CENTRAL DRUGS STANDARD CONTROL ORGANISATION
    * RECEIVED NO OBJECTION FOR DURVALUMAB (IMFINZI™) 120 MG/
2.4 ML
AND 500 MG/ 10 ML SOLUTION FOR INFUSION

Source text for Eikon:  ID: 
Further company coverage:  ASTR.NS 
 ((Reuters.Briefs@thomsonreuters.com;))